Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 6:19:100454.
doi: 10.1016/j.ymgmr.2019.100454. eCollection 2019 Jun.

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts

Dominique P Germain  1 , Perry M Elliott  2 , Bruno Falissard  3 , Victor V Fomin  4 , Max J Hilz  5 , Ana Jovanovic  6 , Ilkka Kantola  7 , Aleš Linhart  8 , Renzo Mignani  9 , Mehdi Namdar  10 , Albina Nowak  11 , João-Paulo Oliveira  12 , Maurizio Pieroni  13 , Miguel Viana-Baptista  14 , Christoph Wanner  15 , Marco Spada  16
Affiliations
Review

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts

Dominique P Germain et al. Mol Genet Metab Rep. .

Abstract

Background: Enzyme replacement therapy (ERT) with recombinant human α-galactosidase has been available for the treatment of Fabry disease since 2001 in Europe and 2003 in the USA. Treatment outcomes with ERT are dependent on baseline patient characteristics, and published data are derived from heterogeneous study populations.

Methods: We conducted a comprehensive systematic literature review of all original articles on ERT in the treatment of Fabry disease published up until January 2017. This article presents the findings in adult male patients.

Results: Clinical evidence for the efficacy of ERT in adult male patients was available from 166 publications including 36 clinical trial publications. ERT significantly decreases globotriaosylceramide levels in plasma, urine, and in different kidney, heart, and skin cell types, slows the decline in estimated glomerular filtration rate, and reduces/stabilizes left ventricular mass and cardiac wall thickness. ERT also improves nervous system, gastrointestinal, pain, and quality of life outcomes.

Conclusions: ERT is a disease-specific treatment for patients with Fabry disease that may provide clinical benefits on several outcomes and organ systems. Better outcomes may be observed when treatment is started at an early age prior to the development of organ damage such as chronic kidney disease or cardiac fibrosis. Consolidated evidence suggests a dose effect. Data described in male patients, together with female and paediatric data, informs clinical practice and therapeutic goals for individualized treatment.

Keywords: ACEi, angiotensin-converting enzyme inhibitor; ANS, autonomic nervous system; ARB, angiotensin receptor blocker; BPI, Brief Pain Inventory; CES-D, Center for Epidemiologic Studies Depression Scale; CNS, central nervous system; CR, case report; CT, clinical trial; ECG, electrocardiogram/electrocardiography; EOW, every other week; ERT, enzyme replacement therapy; Fabry disease; GFR, glomerular filtration rate; GI, gastrointestinal; GL-3, globotriaosylceramide; IENFD, intra-epidermal nerve fibre density; IVST, intraventricular septum thickness; LPWT, left posterior wall thickness; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVM, left ventricular mass; LVMi, left ventricular mass index; LVWT, left ventricular wall thickness; MG, mixed gender; MRI, magnetic resonance imaging; MWT, maximal wall thickness; NYHA, New York Heart Association; OS, observational study; PNS, peripheral nervous system; QoL, quality of life; RCT, randomized controlled trial; SF-36, 36-item Short Form Health Survey; TIA, transient ischaemic attack; WMH, white matter hyperintensities.; adult male patients; agalsidase alfa; agalsidase beta; eGFR, estimated glomerular filtration rate; enzyme replacement therapy; lyso-GL-3, globotriaosylsphingosine; systematic literature review.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Germain D.P. Fabry disease. Orphanet J. Rare Dis. 2010;5:30. - PMC - PubMed
    1. Waldek S., Patel M., Banikazemi M. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet. Med. 2009;11:790–796. - PubMed
    1. Eng C.M., Germain D.P., Banikazemi M. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet. Med. 2006;8:539–548. - PubMed
    1. Germain D.P. A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib. Nephrol. 2001;136:234–240. - PubMed
    1. Germain D.P., Avan P., Chassaing A., Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med. Genet. 2002;3:10. - PMC - PubMed
  NODES
Association 1
INTERN 4
twitter 2